SESSION IV – How I treat relapsed multiple myeloma
Chair : Philippe Moreau (Nantes)
10:10-10:15 Introduction Philippe Moreau (Nantes)
10:15-10:35 Interactive case: Relapsed multiple myeloma Xavier Leleu (Poitiers)
10:35-10:55 Case-based lecture : How I treat first relapse Paula Rodriguez-Otero (Pamplona)
10:55-11:15 Case-based lecture : How I treat later relapses Stefan Knop (Würzburg)
11:15-11:35 Case-based lecture : Novel agents in relapsed Enrique Ocio (Santander)
multiple myeloma
11:35-11:45 Brief oral communications
11:35-11:40 Talquetamab, a G protein-coupled receptor family C Albert Oriol (Barcelona)
group 5 member D (GPRC5D) X CD3 bispecific antibody, in patients with relapsed and/or refractory
multiple myeloma (RRMM): results from an ongoing phase 1 study
11:40-11:45 HORIZON (OP-106): Melflufen plus Dexamethasone in 55 Paul G. Richardson (Boston)
patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD)—
subgroup analysis
11:45-12:10 Panel discussion
12:10-13:05 DEBATE 3 – Should every patient receive daratumumab in first line?
Chair: Niels van de Donk (Amsterdam)
12:10-12:15 Introduction Niels van de Donk (Amsterdam)
Audience votes YES or NO
12:15-12:30 YES Philippe Moreau (Nantes)
12:30-12:45 NO Fredrik Schjesvold (Oslo)
12:45-13:05 Discussion
Audience votes again YES or NO
13:05-14:45 Lunch
13:35-14:35 SATELLITE SYMPOSIUM
New era, new data, new implications for managing multiple myeloma
Speakers: Mohamad Mohty (Paris), Philippe Moreau (Nantes)
This symposium is supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
4